Medtide Inc. (03880.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 2.94B

MomentumView details →

1D Return

−1.80%

YTD Return

−32.02%

RSI (14)

40.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

Market Cap

HKD 2.94B

RSI (14)

40.5

MomentumView details →

1D Return

−1.80%

YTD Return

−32.02%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

HKD 0.06

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Next earningsMar 3, 2027 →

Latest newsMore news →

Tide Pharmaceutical (03880.HK) reported interim results for the six months ended June 2026, with revenue of RMB 235 million, down 7.6% year-on-year, and net profit of RMB 53.68 million, down 47.4% year-on-year.9d ago

Similar companies

Zai Lab LimitedZLAB 寿仙谷603896.SH MBX Biosciences, Inc. Common StockMBX Arcutis Biotherapeutics, Inc.ARQT NewAmsterdam Pharma Company N.V.NAMS Immunome, Inc.IMNM Find similar companies →

Latest newsMore news →

Tide Pharmaceutical (03880.HK) reported interim results for the six months ended June 2026, with revenue of RMB 235 million, down 7.6% year-on-year, and net profit of RMB 53.68 million, down 47.4% year-on-year.9d ago